SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)


Por: del Alba A, Mendez-Vidal M, Vazquez S, Castro E, Climent M, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto J, Arranz J

Publicada: 1 may 2021 Ahead of Print: 1 feb 2021
Resumen:
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanced prostate cancer allowing a better selection of therapies in each patient. Tumor testing for BRCA1 and BRCA2 is recommended for patients with metastatic prostate cancer, also considering a broad panel to guide decisions and genetic counseling. In symptomatic metastatic patients, castration should be stared to palliate symptoms and prolong survival. In high-risk or high-volume metastatic hormone-naive patients, castration should be combined with docetaxel, abiraterone, enzalutamide or apalutamide. Radiotherapy to the primary tumor combined with systemic therapy is recommended in low-volume mHNPC patients. In patients with non-metastatic castration-resistant tumors, risk stratification can define the frequency of imaging. Adding enzalutamide, darolutamide or apalutamide to these patients prolongs metastasis-free and overall survival, but potential adverse events need to be taken into consideration. The choice of docetaxel, abiraterone or enzalutamide for treating metastatic castration-resistant patients depends on previous therapies, with cabazitaxel being also recommended after docetaxel. Olaparib is recommended in BRCA1/BRCA2 mutated castration-resistant patients after progression on at least one new hormonal therapy. Aggressive variants of prostate cancer respond to platinum-based chemotherapy. To optimize treatment efficiency, oncologists should incorporate all of these advances into an overall therapeutic strategy.

Filiaciones:
del Alba A:
 Hosp Univ Puerta Hierro Majadahonda, Med Oncol Dept, Joaquin Rodrigo 2, Madrid 28222, Spain

Mendez-Vidal M:
 Hosp Univ Reina Sofia, Maimonides Inst Biomed Res Cordoba IMIBIC, Med Oncol Dept, Cordoba, Spain

Vazquez S:
 Hosp Univ Lucus Augusti, Med Oncol Dept, Lugo, Spain

Castro E:
 Hosp Univ Virgen Victoria & Reg Malaga, Med Oncol Dept, Malaga, Spain

Climent M:
 Fdn Inst Valenciano Oncol, Med Oncol Dept, Valencia, Spain

Gallardo E:
 Univ Autonoma Barcelona, Med Oncol Dept, Parc Tauli Hosp Univ, Inst Invest & Innovacio Parc Tauli I3PT, Sabadell, Spain

Gonzalez-Billalabeitia E:
 Hosp Univ Doce Octubre, Inst Imas12, Med Oncol Dept, Madrid, Spain

 Univ Catolica San Antonio Murcia UCAM, Murcia, Spain

Lorente D:
 Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain

Maroto J:
 Hosp Univ Santa Creu & San Pau, Med Oncol Dept, Barcelona, Spain

Arranz J:
 Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
SPRINGER-VERLAG ITALIA SRL, VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Italia
Tipo de documento: Article
Volumen: 23 Número: 5
Páginas: 969-979
WOS Id: 000621317100001
ID de PubMed: 33625671
imagen hybrid, Green Published

MÉTRICAS